Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
January 04, 2024 07:30 ET
|
Sensei Biotherapeutics
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024...
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 07, 2023 07:30 ET
|
Sensei Biotherapeutics
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported...
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
November 03, 2023 16:05 ET
|
Sensei Biotherapeutics
- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose...
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
November 01, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
October 25, 2023 09:05 ET
|
Sensei Biotherapeutics
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
October 23, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
September 27, 2023 07:30 ET
|
Sensei Biotherapeutics
- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety...
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
September 21, 2023 07:30 ET
|
Sensei Biotherapeutics
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile - - Mechanistic mouse data show SNS-101 drives tumor macrophages to...
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
September 13, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
August 30, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...